Shopping Cart
Remove All
Your shopping cart is currently empty
Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $239 | In Stock | In Stock | |
| 5 mg | $787 | In Stock | In Stock | |
| 10 mg | $1,230 | - | In Stock | |
| 25 mg | $2,380 | - | In Stock | |
| 50 mg | $3,230 | - | In Stock |
| Description | Tafasitamab (XmAb5574) is an FC-modified humanized monoclonal antibody targeting the human B-cell surface antigen CD19 for the study of diffuse large B-cell lymphoma. |
| In vitro | In an E/T ratio-dependent manner, tafasitamab (XmAb5574) induced cytotoxicity to Mino and Jeko (MCL) cell lines. It also increased antibody-dependent cellular phagocytosis (ADCP) and antiproliferative activity. Additionally, tafasitamab (XmAb5574) can enhance the anti-proliferative activity induced by caspase-mediated apoptosis[1][2]. |
| In vivo | In a xenograft tumor model of disseminated BL mice, tafasitamab (2.5 μg/kg, once on day 1) inhibited lymphoma growth[1]. |
| Synonyms | XmAb5574, Tafasitamab-cxix, MOR00208 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 147.41 kDa |
| Cas No. | 1422527-84-1 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.